Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sihuan Pharma In-Licenses Two CCV Products from NeuroVive of Sweden

publication date: Nov 20, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sihuan Pharmaceutical, China’s largest cerebral-cardiovascular drugmaker, bought China rights to two clinical-stage drugs from NeuroVive Pharmaceutical AB of Sweden: CicloMulsion® treats heart reperfusion injuries and NeuroSTAT® is given to patients who have suffered a traumatic brain injury. Sihuan will pay 47 million RMB ($7.2 million) for the two products in a combination of upfront and milestone payments. It will also pay a royalty of 10% on revenues for ten years from launch. More details....

Stock Symbol: (HK: 0460)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors